Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.
Meenakshi Prabhune, PhD | Feb 23, 2024 | 10 min read
With deep learning methods revolutionizing life sciences, researchers bet on de novo proteins and cell mapping models to deliver customized precision medicines.
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Charlene Lancaster, PhD | Mar 12, 2024 | 4 min read
Using a circuit-based system, scientists determined the ideal transcription factor levels to promote the successful reprogramming of fibroblasts into induced pluripotent stem cells.
Using lentiviral vectors to replace mutated genes in blood stem cells, scientists successfully treat two rare diseases apparently without causing harmful side effects.